October 14, 2016
Cambridge, MA

Solid Adds Galectin-1 To Disease Modifying Therapy Pipeline

Over the past several months, Solid has continued to build its pipeline of therapeutic candidates that have the potential to address the full spectrum of Duchenne muscular dystrophy (DMD).

We are excited to announce a new collaboration with Dr. Dean Burkin of the University of Nevada and Strykagen to develop Galectin-1, a candidate that has the potential to aid in muscle regeneration and repair.

In DMD patients, the loss of dystrophin leads to an unstable muscle membrane, resulting in muscle damage, inflammation and degeneration. Galectin-1 is a protein found in muscle that has the potential to stabilize the muscle membrane through multiple novel pathways. 

In preclinical studies, administration of the recombinant Galectin-1 protein has improved muscle integrity and strength. With further research, we believe that Galectin-1 has the potential to aid in muscle renewal and repair, increase blood supply and reduce inflammation. In addition, if successful Galectin-1 has the potential to complement future gene therapy approaches.

The Galectin-1 program is currently in preclinical development. Solid is excited to work with Dr. Burkin and his team to progress Galectin-1 through development and potentially limit the impact of dystrophin absence on muscle health and function.

VIEW OUR PIPELINE

Related news

Jan30

The Duchenne Research Fund (DRF) provided Solid with a research grant of $600,000 to support its LTBP4 program to combat fibrosis and to support novel biomarker work in Duchenne muscular dystrophy (DMD).

Nov10

Grant from Duchenne UK to fund research to better understand the potential benefits of statins in patients with Duchenne muscular dystrophy (DMD).

Jun09

The biologic candidate LTBP4 has the potential to promote muscle health and reduce fibrosis in patients with Duchenne muscular dystrophy.

May28

Carl Morris, Solid Biosciences’ vice president of Research and Development, speaks about being a “Game Changer in Rare Disease.”

Dec08

Debiopharm International SA and Solid Biosciences, LLC, announce a collaboration to explore the use of Alisporivir (Debio 025) in muscular dystrophy.

More information about Solid?

Please subscribe to receive our latest news